Biohaven

Biohaven Current Liabilities

The Current Liabilities of Biohaven (BHVN) as of Nov 12, 2026 is 115.93 M USD. In the previous year, Current Liabilities was 205.71 M USD — a change of -43.64% (lower).

Current Liabilities

115.93 MUSD

YoY

-43.64%

Last updated:

Current Liabilities of Biohaven is 2025 115.93 M USD. Current Liabilities of Biohaven was 2024 205.71 M USD. It decreases by -43.64% lower compared to the previous year.

The Biohaven Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
28.33 M USD
Jan 1, 2019
118.27 M USD
Jan 1, 2020
63.25 M USD
Jan 1, 2021
84.98 M USD
Jan 1, 2022
134.12 M USD
Jan 1, 2023
130.97 M USD
Jan 1, 2024
205.71 M USD
Jan 1, 2025
115.93 M USD
The Biohaven Current Liabilities history
YEARCurrent LiabilitiesYoY
115.93 MUSD-43.64%
205.71 MUSD+57.07%
130.97 MUSD-2.35%
134.12 MUSD+57.82%
84.98 MUSD+34.36%
63.25 MUSD-46.52%
118.27 MUSD+317.42%
28.33 MUSD+100.54%
14.13 MUSD+78.85%
7.90 MUSD+1,875.00%
400,000.00USD+300.00%
100,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biohaven Stock analysis

What does Biohaven do? Biohaven Pharmaceutical Holding Co. Ltd. generates revenue through the research and development of late-stage product candidates targeting neurological diseases and rare disorders. The company utilizes its glutamate platform to advance clinical-stage compounds for various indications, including trigriluzole for obsessive-compulsive disorder, spinocerebellar ataxia, and Alzheimer's disease. Additionally, the firm develops BHV-0223 for amyotrophic lateral sclerosis and BHV-5000 for conditions such as Rett syndrome, neuropathic pain, and treatment-resistant depression. The business model focuses on identifying and developing clinical-stage compounds that target orphan neurologic indications and other neurological pathways, with the company currently employing 825 full-time employees in New Haven, Connecticut. Biohaven is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biohaven stock

Current Liabilities of Biohaven is 115.93 M USD in 2025.

Current Liabilities of Biohaven changed from 205.71 M USD to 115.93 M USD, representing a -43.64% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Biohaven since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Biohaven historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Biohaven

All Key Metrics — Biohaven